Article Listing - Uptake of the first oral MS therapies will result in the market value peaking at $8.4 billion in 2013

APPOINTMENTS AT OTSUKA

25 May 1992

- Appointments at Otsuka: Tamotsu Fujino becomes vice director, liaison with licensors, at the Tokyo office of corporate planning; Jun'ichi...

ELI LILLY: DES SETTLEMENT

25 May 1992

- Eli Lilly has arrived at an out- of-court settlement with a New York woman, whose mother had taken the...

IMMUNE RESPONSE AND R-PR: AIDS INVESTMENT

25 May 1992

- Immune Response Corp and Rhone-Poulenc Rorer have agreed a further investment of $9 million each in their joint AIDS...

LOSEC SALES ROCKET FOR ASTRA

25 May 1992

Reporting first-quarter 1992 turn-over up 35% at 3.7 billion Swed-ish kroner, Sweden's Astra AB notes that sales of its proton...

ASTRA'S PLENDIL HEADING FOR CHF INDICATION

25 May 1992

Currently approved for use as an antihypertensive, Astra's third generation dihydropyridine vasoselective calcium channel blocker Plendil (felodipine) may also represent...

UK BIOTECH COS PLAN FLOTATIONS

25 May 1992

Two of the UK's largest biotechnol-ogy concerns, Celltech and British Biotechnology, have plans to float their companies on the stock...

FDA PANEL'S POSITIVE REVIEW ON HALCION

25 May 1992

Following the US Food and Drug Administration's Psychopharmacol-ogical Drug Products Advisory Committee's conclusion that Upjohn's Halcion (triazolam) is safe and...